. Author manuscript; available in PMC: 2009 Oct 26.

Published in final edited form as: J Nucl Med. 2008 Jun 13;49(7):1066–1074. doi: 10.2967/jnumed.107.049502

Table 3.

Summary of kinetic and uptake data for patients. Values are mean parameter estimates for each administered mass of huJ591. Quoted uncertainties are standard errors of the mean.

	10mg	25mg	50mg	100mg
Whole body T_{1/2 biol} (days) ^*	8.5 (± 0.8)	12.8 (± 1.5)	17.7 (± 2.2)	23.1 (± 3.7)
Serum T_{1/2 biol} (days) ^§	0.96 (± 0.07)	1.94 (± 0.15)	2.78 (± 0.22)	3.49 (± 0.28)
Whole body residence time (hr)	71 (± 2)	77 (± 2)	82 (± 2)	84 (± 2)
Serum residence time (hr)	24 (± 1)	39 (± 2)	47 (± 2)	53 (± 2)
Liver residence time (hr)	21 (± 1)	15 (± 1)	13 (± 2)	10 (± 1)
Lesion residence time (hr)	0.29 (± 0.05)	0.38 (± 0.07)	0.43 (± 0.06)	0.45 (± 0.08)
Relative liver uptake ^#	1.0	0.70 (± 0.03)	0.65 (± 0.11)	0.48 (± 0.07)
Relative lesion uptake ^$	1.0	1.32 (± 0.04)	1.80 (± 0.14)	1.67 (± 0.13)

Statistical significance of the differences between groups assessed by paired t-test:

all intergroup differences significant (P<0.05) except 50mg vs. 100mg

^§

all intergroup differences significant (P<0.05)

all intergroup differences significant (P<0.05) except 25mg vs. 50mg

all intergroup differences significant (P<0.05) except 50mg vs. 100mg